Maurício Silva dos Santos

Prof. Maurício Silva dos Santos

Federal University of Itajubá
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
JFJessica Venancia Faria
Jessica Venancia Faria
PVPercilene Fazolin Vegi
Percilene Fazolin Vegi
AMAna Gabriella Carvalho Miguita
Ana Gabriella Carvalho Miguita
Maurício Silva dos SantosMaurício Silva dos Santos
Maurício Silva dos Santos
NBNubia Boechat
Nubia Boechat
ABAlice Maria Rolim Bernardino
Alice Maria Rolim Bernardino

1 November 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MMM.E. Monteiro
M.E. Monteiro
GLG. Lechuga
G. Lechuga
LLLeonardo da Silva Lara
Leonardo da Silva Lara
BSBernardo Araujo Souto
Bernardo Araujo Souto
MVM.G. Viganó
M.G. Viganó
MPMirian Claudia Pereira
Mirian Claudia Pereira

8 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
LOLorraine Martins Rocha Orlando
Lorraine Martins Rocha Orlando
GLGuilherme Lechuga
Guilherme Lechuga
LLLeonardo da Silva Lara
Leonardo da Silva Lara
BFByanca Silva Ferreira
Byanca Silva Ferreira
CPCynthia Nathalia Pereira
Cynthia Nathalia Pereira
MPMirian Claudia Pereira
Mirian Claudia Pereira
Chagas disease, a chronic and silent disease caused by Trypanosoma cruzi, is currently a global public health problem. The treatment of this neglected disease relies on benznidazole and nifurtimox, two nitroheterocyclic drugs that show limited efficacy and severe side effects. The failure of potential drug candidates in Chagas disease clinical trials highlighted the urgent need to identify new effective chemical entities and more predictive tools to improve translational success in the drug development pipeline. In this study, we designed a small library of pyrazole derivatives (44 analogs) based on a hit compound, previously identified as a T. cruzi cysteine protease inhibitor. The in vitro phenotypic screening revealed compounds 3g, 3j, and 3m as promising candidates, with IC50 values of 6.09 ± 0.52, 2.75 ± 0.62, and 3.58 ± 0.25 µM, respectively, against intracellular amastigotes. All pyrazole derivatives have good oral bioavailability prediction. The structure–activity relationship (SAR) analysis revealed increased potency of 1-aryl-1H-pyrazole-imidazoline derivatives with the Br, Cl, and methyl substituents in the para-position. The 3m compound stands out for its trypanocidal efficacy in 3D microtissue, which mimics tissue microarchitecture and physiology, and abolishment of parasite recrudescence in vitro. Our findings encourage the progression of the promising candidate for preclinical in vivo studies.

5 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LLLeonardo da Silva Lara
Leonardo da Silva Lara
GLGuilherme Lechuga
Guilherme Lechuga
LOLorraine Martins Rocha Orlando
Lorraine Martins Rocha Orlando
BFByanca Silva Ferreira
Byanca Silva Ferreira
BSBernardo Araujo Souto
Bernardo Araujo Souto
MPMirian Claudia Pereira
Mirian Claudia Pereira
Chagas disease, a century-old disease that mainly affects the impoverished population in Latin America, causes high morbidity and mortality in endemic countries. The available drugs, benznidazole (Bz) and nifurtimox, have limited effectiveness and intense side effects. Drug repurposing, and the development of new chemical entities with potent activity against Trypanosoma cruzi, are a potential source of therapeutic options. The present study describes the biological activity of two new series of pyrazole-thiazoline derivatives, based on optimization of a hit system 5-aminopyrazole-imidazoline previously identified, using structure–activity relationship exploration, and computational and phenotype-based strategies. Promising candidates, 2c, 2e, and 2i derivatives, showed good oral bioavailability and ADMET properties, and low cytotoxicity (CC50 > 100 µM) besides potent activity against trypomastigotes (0.4–2.1 µM) compared to Bz (19.6 ± 2.3 µM). Among them, 2c also stands out, with greater potency against intracellular amastigotes (pIC50 = 5.85). The selected pyrazole-thiazoline derivatives showed good permeability and effectiveness in the 3D spheroids system, but did not sustain parasite clearance in a washout assay. The compounds’ mechanism of action is still unknown, since the treatment neither increased reactive oxygen species, nor reduced cysteine protease activity. This new scaffold will be targeted to optimize in order to enhance its biological activity to identify new drug candidates for Chagas disease therapy.

17 April 2019 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
GRGetúlio de S. Rosa
Getúlio de S. Rosa
BSBernardo Araujo Souto
Bernardo Araujo Souto
CPCynthia N. Pereira
Cynthia N. Pereira
BTBruna C. Teixeira
Bruna C. Teixeira
Maurício Silva dos SantosMaurício Silva dos Santos
Maurício Silva dos Santos

27 July 2024 in Molecules
Verified
Journal Article
Open access
PDF file
TSThamyris Perez de Souza
Thamyris Perez de Souza
LOLorraine Martins Rocha Orlando
Lorraine Martins Rocha Orlando
LLLeonardo da Silva Lara
Leonardo da Silva Lara
VPVitoria Barbosa Paes
Vitoria Barbosa Paes
LDLucas Penha Dutra
Lucas Penha Dutra
MPMirian Claudia Pereira
Mirian Claudia Pereira
Chagas disease, a silent but widespread disease that mainly affects a socioeconomically vulnerable population, lacks innovative safe drug therapy. The available drugs, benznidazole and nifurtimox, are more than fifty years old, have limited efficacy, and carry harmful side effects, highlighting the need for new therapeutics. This study presents two new series of pyrazole-thiadiazole compounds evaluated for trypanocidal activity using cellular models predictive of efficacy. Derivatives 1c (2,4-diCl) and 2k (4-NO2) were the most active against intracellular amastigotes. Derivative 1c also showed activity against trypomastigotes, with the detachment of the flagellum from the parasite body being a predominant effect at the ultrastructural level. Analogs have favorable physicochemical parameters and are predicted to be orally available. Drug efficacy was also evaluated in 3D cardiac microtissue, an important target tissue of Trypanosoma cruzi, with derivative 2k showing potent antiparasitic activity and a significant reduction in parasite load. Although 2k potentially reduced parasite load in the washout assay, it did not prevent parasite recrudescence. Drug combination analysis revealed an additive profile, which may lead to favorable clinical outcomes. Our data demonstrate the antiparasitic activity of pyrazole-thiadiazole derivatives and support the development of these compounds using new optimization strategies.